Market Overview

UPDATE: Jefferies Upgrades Vanda Pharmaceuticals to Buy on Tasimelteon Catalyst

Related VNDA
Morning Market Movers
Benzinga's Top #PreMarket Gainers

Jefferies upgraded Vanda Pharmaceuticals (NASDAQ: VNDA) from Hold to Buy and raised the price target from $3.50 to $6.00.

Jefferies commented, "We're finally giving credit for tasimelteon given 1) surprisingly good recent Non24 Ph.3 data w/clinical sleep efficacy which likely improves FDA receptivity, 2) orphan pricing not confounded by ‘depression' efforts, and 3) approaching regulatory catalysts. We still think it's far from a slam dunk, but even conservatively discounted Tasi contribution is likely big upside from current negative EV level."

Vanda Pharmaceuticals closed at $3.95 on Wednesday.

Latest Ratings for VNDA

DateFirmActionFromTo
Jun 2014Empire Asset ManagementInitiates Coverage onSell
Feb 2014Piper JaffrayMaintainsOverweight
Nov 2013Piper JaffrayInitiates Coverage onOverweight

View More Analyst Ratings for VNDA
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Upgrades Analyst Ratings

 

Related Articles (VNDA)

Around the Web, We're Loving...

Get Benzinga's Newsletters